跳到正文
原文
Medical Xpress·· 21 天前AI 评分61

阻断 miR-31-5p 与 CTR 相互作用在小鼠中逆转心房纤维化并减少异常心律

New treatment reduces heart scarring and abnormal heart rhythms, offering a possibility for future therapies

AI 导读

贝勒医学院与牛津大学团队在 Nature Cardiovascular Research 发表研究,设计选择性锁定核酸靶位阻断剂阻断 miR-31-5p 与降钙素受体(CTR)的相互作用,在人心房成纤维细胞中恢复了 CTR 水平。

正文
New treatment reduces heart scarring and abnormal heart rhythms, offering a possibility for future therapies
Atrial fibrosis (by Masson’s trichrome staining) in 24-week-old Lkb1-aKD mice treated with miR-31-5p/CTR-TSB or NC-TSB control. Representative Masson’s trichrome images are shown from biologically independent mice included in the corresponding quantification. Credit: Nature Cardiovascular Research (2026). DOI: 10.1038/s44161-026-00897-1

In a study led by Baylor College of Medicine and the University of Oxford, researchers found that blocking a specific molecular interaction reduced atrial fibrosis in mouse models and cells from human patients with atrial fibrillation (AF), reduced fibrotic responses in human cells, and in the mouse models reversed established atrial fibrosis and reduced abnormal heart rhythms.

The study, published in the latest edition of Nature Cardiovascular Research, points to the potential for a treatment for AF that up until now has not existed.

A gap in AF treatment

"Atrial fibrillation (AF) is the most common arrhythmia, affecting more than 10 million adults in the United States. It substantially raises the risk of ischemic stroke, heart failure, myocardial infarction and can even increase the risk of dementia and kidney disease," said Dr. Xander Wehrens, professor and director of the Cardiovascular Research Institute at Baylor and co-senior author on the paper.

"There are current treatments that help improve heart rhythm but nothing that stops and reverses progression. Our findings open the door to the potential for an effective treatment."

Dr. Svetlana Reilly, associate professor of cardiovascular science at the University of Oxford and co-senior author on the paper, says the findings address a gap in treatment options.

"Atrial fibrosis is a major unmet clinical problem in atrial fibrillation, and currently we have no therapies that directly target the scarring process itself," Reilly said. "Our findings identify a promising therapeutic pathway and suggest that targeted interventions may offer a new strategy for preventing or reversing the structural remodeling that underlies disease progression."

Atrial fibrillation, commonly called AFib, is when the heart's upper chambers beat irregularly, causing the buildup of scar tissue that changes the heart's structure and makes abnormal heart rhythms more likely to develop.

A molecular trigger for scarring

Researchers focused on a small molecule called microRNA-31-5p (miR-31-5p), which helps regulate gene activity inside cells. Patients with AF have elevated levels of this molecule in atrial fibroblasts.

The molecule reduces the production of a protein known as the calcitonin receptor (CTR), which helps control fibroblasts, the cells responsible for producing materials that support heart tissue. When CTR levels fall, fibroblasts can become overactive, leading to scar tissue.

New treatment reduces heart scarring and abnormal heart rhythms, offering a possibility for future therapies
MiR-31 exacerbates profibrotic responses in human atrial fibroblasts and promotes atrial fibrosis in vivo in mice. Credit: Nature Cardiovascular Research (2026). DOI: 10.1038/s44161-026-00897-1

Reversing fibrosis in mouse models

Targeting this process, researchers designed a selective locked nucleic acid target-site blocker to prevent miR-31-5p from interacting with the CTR. In human atrial fibroblasts from patients with AF and in mouse models, this treatment restored CTR levels. In mouse models, it prevented the development of atrial fibrosis, reversed established atrial fibrosis (with fibrosis regressing by approximately 30% relative to baseline while untreated controls progressed), and reduced the duration and burden of abnormal heart rhythms.

"We have worked on this line of research for some time and anticipated the outcomes; however, we were surprised to see this treatment led to a reversal of some of the damage," Wehrens said. "More work is needed to understand how this treatment would work in humans, but our findings suggest that targeting this molecular interaction will help prevent further scarring and reduce tissue damage."

Publication details

Jasha Trompf et al., Selective blockade of microRNA-31-5p−calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia burden, Nature Cardiovascular Research (2026). DOI: 10.1038/s44161-026-00897-1

Journal information: Nature Cardiovascular Research

Key medical concepts

Atrial Fibrillation

Clinical categories

Cardiology

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: New treatment reduces heart scarring and abnormal heart rhythms, offering a possibility for future therapies (2026, October 30) retrieved 30 October 2026 from https://medicalxpress.com/news/2026-10-treatment-heart-scarring-abnormal-rhythms.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com